Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Oral vs injectable vs nasal peptide bioavailability

Name: Oral vs injectable vs nasal peptide bioavailability
Published: 2026-10-27

Why most peptides are injected, and what it took to make one work as a pill

Evidence verdict: Oral peptide absorption is very low without special formulation; the best-studied example, oral semaglutide, reaches only about 0.4% to 1% absolute bioavailability.

Last reviewed: Oct 27, 2026

In 30 seconds

Peptides are broken down by stomach acid and digestive enzymes and cross the gut wall poorly. [Lab, review]
Oral semaglutide needed a permeation enhancer (SNAC) and still has an absolute bioavailability of roughly 0.4% to 1% under fasting conditions; in the fed state exposure was essentially absent. [Review]
A product sold as an "oral" or "nasal" version of an injected peptide is not equivalent unless it has its own pharmacokinetic data. [Regulatory principle]
Nasal delivery works for some small approved peptides but varies widely by molecule; no general rule applies (UNVERIFIED for unapproved products).

Why the gut is a barrier

Oral peptides face enzymatic degradation, poor epithelial permeability, gastric conditions and presystemic metabolism (PMID 42687069). [Review]

The SNAC example

SNAC (salcaprozate sodium) is a permeation enhancer used in approved oral products. Proposed mechanisms include raising local pH, inhibiting pepsin, and effects on membranes; reviews note open questions (PMIDs 42797346, 30781867). [Review, Lab] Even so, a 2026 review reports absolute bioavailability of oral semaglutide of about 0.4% to 1% under optimized fasting conditions with restricted water, and plasma levels below quantification in the fed state (PMID 42687069). [Review]

What this means for unapproved products

Formulation is drug-specific. Without published pharmacokinetic studies for the exact product, claims that a capsule, spray or sublingual form matches an injection are unsupported (UNVERIFIED). This page gives no route or dose guidance.

Injection is not risk-free

Injected products bypass the gut barrier but also bypass its protection, so sterility and endotoxin matter (see the sterility and endotoxin guides).

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document. [Controlled study] randomized trial or systematic review of trials. [Observational] market surveillance, pharmacovigilance or cohort data. [Lab] cell, analytical or animal work. [Case] single case report.

Peptide degradation, storage and cold chain, Bacteriostatic water and sterility risks

References

Vahora et al. Semaglutide bioavailability: limitations, formulation innovation and future opportunities. Pharm Res. 2026. PMID 42687069.
Dinkov et al. Salcaprozate sodium as a permeation enhancer: mechanism, applications and unresolved questions. Pharmaceutics. 2026. PMID 42797346.
Twarog C, et al. Intestinal permeation enhancers for oral delivery of macromolecules: SNAC vs sodium caprate (C10). Pharmaceutics. 2019. PMID 30781867.

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.